<DOC>
	<DOCNO>NCT02048488</DOCNO>
	<brief_summary>TSR-011 potent small molecule inhibitor tyrosine kinases involved cancer , include : 1 . Anaplastic lymphoma kinase ( ALK ) 2 . The tropomyosin-related kinase TRKA , TRKB , TRKC This sequential , open-label , non-randomized study dose escalation Phase 1 , follow expansion recommend phase 2 dose .</brief_summary>
	<brief_title>A Phase I/IIa Open-Label , Dose Escalation Cohort Expansion Trial Oral TSR-011 Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>To consider eligible participate study , follow requirement must meet : 1 . Patients Phase 1 must metastatic locally advanced solid tumor fail respond standard therapy 2 . All patient must confirmation either ALK positive TRK positive status . 3 . Patients Phase 1 require measurable disease . All patient Phase 2a require measurable disease RECIST . 4 . All patient enrol study must tumor tissue available . 5 . Patient ( male female ) must ≥ 18 year age ( except age majority 16 year particular country , United Kingdom ) . 6 . Patient must performance status ≤2 ECOG Performance Scale . 7 . Patient must estimate life expectancy least 3 month . 8 . Patients must adequate organ function . 9 . For patient previously treat myelosuppressive therapy , least 3 week must elapse toxicity must recover grade 1 baseline . Nonmyelosuppressive therapy patient must recover treatmentrelated toxicity . Fourteen day must elapse since palliative radiation bone metastasis . 10 . Female patient childbearing potential must negative serum pregnancy test use adequate birth control duration study participation 3 month last dose study drug . 11 . The patient legal representative must able read , understand , provide sign informed consent . 12 . Patient able understand study procedure agree participate study give write informed consent . Patients deem eligible entry study follow criterion meet : 1 . Patient leukemia . 2 . Patient pregnant lactate female . 3 . Patient uncontrolled congestive heart failure , angina , myocardial infarction precede 3 month . 4 . Ongoing cardiac dysrhythmias NCI CTCAE Grade ≥2 , atrial fibrillation grade , QTc interval &gt; 450 msec . 5 . Patients risk factor Torsade de point patient receive concomitant medication QTprolonging medicine . 6 . Patient uncontrolled concurrent medical condition disease . 7 . Patient undergone bone marrow stem cell transplantation past 6 month . 8 . Patient known hypersensitivity component TSR011 excipients . 9 . Patient active uncontrolled infection . 10 . Patient know psychiatric substance abuse disorder . 11 . Patient active second primary malignancy . 12 . Patient observe clinically active central nervous system ( CNS ) metastases carcinomatous meningitis . 13 . Patient severe concurrent disease , judgment Investigator , would preclude study participation . 14 . Patient known HIV positive AIDSrelated illness . 15 . Patient known history active ( treat ) Hepatitis B C. 16 . Patient presence ascites cause significant symptom . 17 . A patient must stop take prescription , overthecounter , herbal remedy know inhibitor inducer CYP3A4/5 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Anaplastic lymphoma kinase</keyword>
	<keyword>ALK tyrosine kinase receptor</keyword>
	<keyword>ALK+</keyword>
	<keyword>TRK+</keyword>
	<keyword>ALK inhibitor</keyword>
	<keyword>TRK inhibitor</keyword>
	<keyword>tropomyosin receptor kinase</keyword>
	<keyword>TRKA</keyword>
	<keyword>TRKB</keyword>
	<keyword>TRKC</keyword>
	<keyword>advanced malignancy</keyword>
</DOC>